AstraZeneca Spends $443M On Lipid Drug Specialist
AstraZeneca PLC has agreed to buy New Jersey-based Omthera Pharmaceuticals Inc. in a deal worth up to $443 million, allowing it to supplement its blockbuster cholesterol drug Crestor with Omthera's upcoming...To view the full article, register now.
Already a subscriber? Click here to view full article